中生制药(01177.HK)「派安普利」於肿瘤免疫治疗学会年会以突破性成果形式发布
中国生物制药(01177.HK)公布,集团与康方生物科技共同开发及商业化的抗PD-1单抗药物「派安普利」用於治疗复发或难治性经典型霍奇金淋巴瘤最新安全性及有效性数据在第35届肿瘤免疫治疗学会年会上以突破性成果(Late Breaking Abstract)形式发布,该研究显示,派安普利单抗在至少进行了2次疗效评估的r/r cHL受试者中表现出显着的临床获益。其中,客观缓解率(ORR)达到83.6%,完全缓解率(CR)达到49.3%,明显高於历史对照,且优於目前有条件获批上市的PD-1单抗已公布数据。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.